AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15726523 — intervention group
Group type: COMPARATOR
Intervention: Concurrent chemotherapy with standard radiation therapy
Number of subjects: 0
Study 15726523 — intervention group
Group type: COMPARATOR
Intervention: Hyperfractionated (twice-daily) radiation therapy plus concomitant chemotherapy
Number of subjects: 0
Study 12374270 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental-directed, peer-assisted ST intervention
Number of subjects: 1084
Study 12374270 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1084
Study 9855432 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine
Number of subjects: 0
Study 7661347 — intervention group
Group type: EXPERIMENTAL
Intervention: 40‐cm2 fentanyl patch and a 60‐cm2 placebo patch
Number of subjects: 143
Study 7661347 — intervention group
Group type: EXPERIMENTAL
Intervention: 60‐cm2 fentanyl patch and a 40‐cm2 placebo patch
Number of subjects: 143
Study 7661347 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 143
Study 3295129 — intervention group
Group type: COMPARATOR
Intervention: Adr (60 mg/m2 IV on day 1) and DTIC (250 mg/m2 every 3 weeks)
Number of subjects: 335
Study 3295129 — intervention group
Group type: EXPERIMENTAL
Intervention: Adr (60 mg/m2 IV on day 1), DTIC (250 mg/m2 every 3 weeks), and Cyclophosphamide (500 mg/m2 on day 1)
Number of subjects: 335
Study 3295129 — intervention group
Group type: EXPERIMENTAL
Intervention: Adr (60 mg/m2 IV on day 1), DTIC (250 mg/m2 every 3 weeks), and Actinomycin D (1.2 mg/m2 on day 1)
Number of subjects: 335
Study 31990207 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine (10 mg/day)
Number of subjects: 0
Study 31990207 — intervention group
Group type: COMPARATOR
Intervention: Venlafaxine XR (150 mg/day)
Number of subjects: 0
Study 29535136 — intervention group
Group type: EXPERIMENTAL
Intervention: Mapping-guided ablation followed by modified circumferential pulmonary vein (PV) ablation (n=41)
Number of subjects: 81
Study 29535136 — intervention group
Group type: COMPARATOR
Intervention: Modified circumferential PV ablation alone (control group, n=40)
Number of subjects: 81
Study 29535136 — intervention group
Group type: EXPERIMENTAL
Intervention: Mapping-guided ablation (n=41)
Number of subjects: 81
Study 26801067 — intervention group
Group type: EXPERIMENTAL
Intervention: In-bag protected morcellation
Number of subjects: 104
Study 26801067 — intervention group
Group type: COMPARATOR
Intervention: Uncontained power myoma removal
Number of subjects: 104
Study 25641922 — intervention group
Group type: EXPERIMENTAL
Intervention: CLA80:20 (4 g/day)
Number of subjects: 43
Study 25641922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 24119523 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional betamethasone (1.4 mg)
Number of subjects: 59
Study 24119523 — intervention group
Group type: COMPARATOR
Intervention: Intralesional triamcinolone acetonide (8 mg)
Number of subjects: 59
Study 20958852 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 231
Study 18211495 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined TAIL + IFN-alpha2b group
Number of subjects: 19
Study 18211495 — intervention group
Group type: COMPARATOR
Intervention: TAIL-only group
Number of subjects: 19
Study 19148563 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate treatment
Number of subjects: 249
Study 19148563 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 249
Study 16366765 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg Diazepam (DZ)
Number of subjects: 22
Study 16366765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 11564386 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg once daily (n = 108)
Number of subjects: 215
Study 11564386 — intervention group
Group type: COMPARATOR
Intervention: Cerivastatin 0.3 mg once daily (n = 107)
Number of subjects: 215
Study 11564386 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg once daily
Number of subjects: 215
Study 11564386 — intervention group
Group type: COMPARATOR
Intervention: Cerivastatin 0.3 mg once daily
Number of subjects: 215
Study 9784902 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinell (nicotine patches)
Number of subjects: 106
Study 9784902 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 106
Study 7945141 — intervention group
Group type: EXPERIMENTAL
Intervention: Cued targets (Valid) in visual modality
Number of subjects: 0
Study 7945141 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncued targets (Invalid) in visual modality
Number of subjects: 0
Study 7945141 — intervention group
Group type: EXPERIMENTAL
Intervention: Cued targets (Valid) in auditory modality
Number of subjects: 0
Study 7945141 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncued targets (Invalid) in auditory modality
Number of subjects: 0
Study 3555877 — intervention group
Group type: COMPARATOR
Intervention: Normal saline IV three minutes and again immediately prior to succinylcholine
Number of subjects: 395
Study 3555877 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.06 mg X kg‐1 d‐tubo‐curarine (dTc) IV three minutes prior and normal saline IV immediately prior
Number of subjects: 395
Study 3555877 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline IV three minutes prior and 1.5 mg X kg‐1 lidocaine IV immediately prior
Number of subjects: 395
Study 3555877 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.06 mg X kg‐1 dTc IV three minutes prior and 1.5 mg X kg‐1 lidocaine IV immediately prior
Number of subjects: 395
Study 31066715 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed recruitment approach (including opportunistic methods, social media, and local organizations)
Number of subjects: 10691
Study 31066715 — intervention group
Group type: EXPERIMENTAL
Intervention: Facebook and mailing lists
Number of subjects: 10691
Study 31066715 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct street recruitment
Number of subjects: 10691
Study 31066715 — intervention group
Group type: COMPARATOR
Intervention: Random sampling in Örebro
Number of subjects: 10691
Study 30146493 — intervention group
Group type: EXPERIMENTAL
Intervention: External expert consultation model (workshop, therapy manual, expert follow-up consultation)
Number of subjects: 26
Study 30146493 — intervention group
Group type: COMPARATOR
Intervention: Train-the-trainer model (staff member coached to train others)
Number of subjects: 26
Study 30146493 — intervention group
Group type: EXPERIMENTAL
Intervention: External expert consultation model
Number of subjects: 26
Study 30146493 — intervention group
Group type: COMPARATOR
Intervention: Train-the-trainer model
Number of subjects: 26
Study 28186934 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week mindfulness course
Number of subjects: 550
Study 28186934 — intervention group
Group type: COMPARATOR
Intervention: Mental health provision as usual
Number of subjects: 550
Study 25187423 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-week moderate-intensity physical activity intervention
Number of subjects: 271
Study 25187423 — intervention group
Group type: COMPARATOR
Intervention: Control group (no physical activity intervention)
Number of subjects: 271
Study 22919767 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based patient education
Number of subjects: 0
Study 22919767 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face education with a nurse
Number of subjects: 0
Study 19605623 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based surveys
Number of subjects: 0
Study 19605623 — intervention group
Group type: COMPARATOR
Intervention: Paper surveys
Number of subjects: 0
Study 19605623 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-mode surveys
Number of subjects: 0
Study 17230050 — intervention group
Group type: EXPERIMENTAL
Intervention: Cue exposure therapy (CET)
Number of subjects: 127
Study 17230050 — intervention group
Group type: COMPARATOR
Intervention: Placebo psychotherapy treatment (PPT)
Number of subjects: 127
Study 15302737 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux (2.5 mg once daily)
Number of subjects: 5385
Study 15302737 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin (approved regimens)
Number of subjects: 5385
Study 11245762 — intervention group
Group type: EXPERIMENTAL
Intervention: Aided wheelies (AW)
Number of subjects: 42
Study 11245762 — intervention group
Group type: COMPARATOR
Intervention: Conventional wheelies (CW)
Number of subjects: 42
Study 10225047 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 week course of 70 degrees head-up tilt for 30 min daily (Group-I)
Number of subjects: 20
Study 10225047 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific yogic exercises equivalent to head-up or head-down tilt for 30 min daily (Group-II)
Number of subjects: 20
Study 7870559 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training (5 sessions of 1.5 hours each)
Number of subjects: 57
Study 7870559 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise reduction (to no more than 5 hours of aerobic activity per week)
Number of subjects: 57
Study 7870559 — intervention group
Group type: COMPARATOR
Intervention: Control group (maintained current exercise regimen)
Number of subjects: 57
Study 3367001 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable rate pacing (VVIR)
Number of subjects: 16
Study 3367001 — intervention group
Group type: COMPARATOR
Intervention: Single rate demand pacing (VVI)
Number of subjects: 16
Study 30461319 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic carpal tunnel release (ECTR)
Number of subjects: 30
Study 30461319 — intervention group
Group type: COMPARATOR
Intervention: Open carpal tunnel release (OCTR)
Number of subjects: 30
Study 29020191 — intervention group
Group type: EXPERIMENTAL
Intervention: TST/QFT arm
Number of subjects: 871
Study 29020191 — intervention group
Group type: COMPARATOR
Intervention: TST arm
Number of subjects: 871
Study 27027501 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + AMX + MET (500 mg × 3 times daily for 3 days)
Number of subjects: 102
Study 27027501 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + AMX + MET (500 mg × 3 times daily for 7 days)
Number of subjects: 102
Study 27027501 — intervention group
Group type: COMPARATOR
Intervention: SRP + placebo
Number of subjects: 102
Study 25209620 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated disease management intervention delivered by trained general practitioners, practice nurses, and specialised physiotherapists.
Number of subjects: 1086
Study 25209620 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated disease management intervention
Number of subjects: 1086
Study 25209620 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1086
Study 23535525 — intervention group
Group type: EXPERIMENTAL
Intervention: ABBS±ACE‐I (Aspirin, Beta-blockers, Statins, with/without Angiotensin-converting enzyme inhibitor) (n=513)
Number of subjects: 819
Study 23535525 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (A)
Number of subjects: 819
Study 23535525 — intervention group
Group type: COMPARATOR
Intervention: Beta-blockers (BB)
Number of subjects: 819
Study 23535525 — intervention group
Group type: COMPARATOR
Intervention: Statins (S)
Number of subjects: 819
Study 23535525 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin-converting enzyme inhibitor (ACE-I)
Number of subjects: 819
Study 20883265 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesotherapy administration of meglumine antimoniate
Number of subjects: 85
Study 20883265 — intervention group
Group type: COMPARATOR
Intervention: Conventional injection of meglumine antimoniate
Number of subjects: 85
Study 17941902 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide Autogel (LAN)
Number of subjects: 12
Study 17941902 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide long-acting repeatable (OCT)
Number of subjects: 12
Study 16622372 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined one-stage anterior stabilization with mesh cage and SSTF (Group A)
Number of subjects: 40
Study 16622372 — intervention group
Group type: COMPARATOR
Intervention: Solely SSTF with intermediate screws in the fractured vertebra (Group B)
Number of subjects: 40
Study 12622937 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem 500 mg every 12 hours (or 1 g every 12 hours if necessary)
Number of subjects: 182
Study 12622937 — intervention group
Group type: COMPARATOR
Intervention: Imipenem/cilastatin 500 mg/500 mg every 12 hours (or 1 g every 12 hours if necessary)
Number of subjects: 182
Study 10626827 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetate-free biofiltration (AFB) with AN69 membrane and bicarbonate solution infusion (NaHCO3 145 or 167 mEq/lt)
Number of subjects: 400
Study 10626827 — intervention group
Group type: COMPARATOR
Intervention: Bicarbonate hemodialysis (BD)
Number of subjects: 400
Study 10626827 — intervention group
Group type: EXPERIMENTAL
Intervention: Both AFB and BD
Number of subjects: 400
Study 7491551 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate, 750 micrograms/day
Number of subjects: 21
Study 7491551 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate, 1500 micrograms/day
Number of subjects: 21
Study 1838460 — intervention group
Group type: EXPERIMENTAL
Intervention: History of back injury claim
Number of subjects: 228
Study 1838460 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 228
Study 1838460 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter duration of employment
Number of subjects: 228
Study 1838460 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent job change
Number of subjects: 228
Study 1838460 — intervention group
Group type: EXPERIMENTAL
Intervention: History of non‐back injury claim
Number of subjects: 228
Study 1838460 — intervention group
Group type: EXPERIMENTAL
Intervention: Overtime and being female among heavy lifters
Number of subjects: 228
Study 6452802 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 75 mg nocte (increasing to 150 mg nocte)
Number of subjects: 12
Study 6452802 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimelidine 100 mg nocte (increasing to 200 mg nocte)
Number of subjects: 12
Study 6452802 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 12
Study 31969173 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose inhaled nitric oxide (5-10 ppm)
Number of subjects: 134
Study 31969173 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 134
Study 30589351 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment integrity procedures
Number of subjects: 270
Study 25644360 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-min modified sham feeding (MSF) with 100 kcal gastric load
Number of subjects: 26
Study 25644360 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-min modified sham feeding (MSF) with 700 kcal gastric load
Number of subjects: 26
Study 25644360 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-min modified sham feeding (MSF) with 100 kcal gastric load
Number of subjects: 26
Study 25644360 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-min modified sham feeding (MSF) with 700 kcal gastric load
Number of subjects: 26
Study 25644360 — intervention group
Group type: COMPARATOR
Intervention: Control (no MSF, 500 mL of water)
Number of subjects: 26
Study 23831385 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined resistance training and aerobic training
Number of subjects: 83
Study 23831385 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration training
Number of subjects: 83
Study 23831385 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 83
Study 21508886 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical total disc replacement (TDR‐C)
Number of subjects: 187
Study 21508886 — intervention group
Group type: COMPARATOR
Intervention: Anterior cervical discectomy and fusion (ACDF)
Number of subjects: 187
Study 19523094 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum chewing (one stick of sugarless gum for 15 minutes every 2 hours after surgery)
Number of subjects: 200
Study 19523094 — intervention group
Group type: COMPARATOR
Intervention: Traditional management (oral intake of clear fluids allowed after passage of flatus and regular diet with the passage of bowel movement)
Number of subjects: 200
Study 17135064 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis (standardized, individual 8‐session hypnosis treatment)
Number of subjects: 30
Study 17135064 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 30
Study 15210926 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraction group
Number of subjects: 83
Study 15210926 — intervention group
Group type: COMPARATOR
Intervention: Non-extraction group
Number of subjects: 83
Study 11466161 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release lovastatin 10 mg
Number of subjects: 0
Study 11466161 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release lovastatin 20 mg
Number of subjects: 0
Study 11466161 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release lovastatin 40 mg
Number of subjects: 0
Study 11466161 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release lovastatin 60 mg
Number of subjects: 0
Study 11466161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10460956 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program of 2 hours duration implemented twice a year
Number of subjects: 297
Study 10460956 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program plus a 0.12% chlorhexidine rinse weekly
Number of subjects: 297
Study 10460956 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program, chlorhexidine rinse, and fluoride varnish application twice a year
Number of subjects: 297
Study 10460956 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions including scaling and root planing every 6 months
Number of subjects: 297
Study 10460956 — intervention group
Group type: COMPARATOR
Intervention: Usual care from a public health department or a private practitioner
Number of subjects: 297
Study 7821093 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha)
Number of subjects: 20
Study 2369034 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophilic contact lenses worn full time
Number of subjects: 0
Study 2369034 — intervention group
Group type: COMPARATOR
Intervention: Spectacles worn as age-matched controls
Number of subjects: 0
Study 290649 — intervention group
Group type: EXPERIMENTAL
Intervention: Stannous fluoride compounds
Number of subjects: 37
Study 290649 — intervention group
Group type: COMPARATOR
Intervention: Placebo compounds
Number of subjects: 37
Study 30360960 — intervention group
Group type: EXPERIMENTAL
Intervention: AlaGln (8 mM)
Number of subjects: 50
Study 30360960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 28101516 — intervention group
Group type: EXPERIMENTAL
Intervention: Postocclusive time to peak flow measured by laser Doppler flowmetry
Number of subjects: 100
Study 28101516 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline microvascular blood flow
Number of subjects: 100
Study 28101516 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous oxygen tension
Number of subjects: 100
Study 23815270 — intervention group
Group type: EXPERIMENTAL
Intervention: Functioning assessment based on the International Classification of Functioning, Disability and Health (ICF)
Number of subjects: 81
Study 23815270 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical assessment
Number of subjects: 81
Study 23161049 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezoelectric surgery (PS Group)
Number of subjects: 12
Study 23161049 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional rotary osteotomy technique (RT Group)
Number of subjects: 12
Study 20025830 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut supplementation (about 77 g) with habitual diet for 4 weeks
Number of subjects: 54
Study 18367384 — intervention group
Group type: EXPERIMENTAL
Intervention: APTD (acute phenylalanine/tyrosine depletion)
Number of subjects: 16
Study 18367384 — intervention group
Group type: EXPERIMENTAL
Intervention: APTD + L-DOPA
Number of subjects: 16
Study 18367384 — intervention group
Group type: COMPARATOR
Intervention: BAL (nutritionally balanced amino acid mixture)
Number of subjects: 16
Study 15866255 — intervention group
Group type: EXPERIMENTAL
Intervention: Group detailing (N=227 prescribers)
Number of subjects: 9820
Study 15866255 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual detailing (N=235 prescribers)
Number of subjects: 9820
Study 15866255 — intervention group
Group type: COMPARATOR
Intervention: Usual care (N=319 prescribers)
Number of subjects: 9820
Study 14599264 — intervention group
Group type: EXPERIMENTAL
Intervention: Single target (cocaine only)
Number of subjects: 58
Study 14599264 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual target (cocaine and heroin)
Number of subjects: 58
Study 10645328 — intervention group
Group type: EXPERIMENTAL
Intervention: Low serum total cholesterol
Number of subjects: 29133
Study 10645328 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 29133
Study 8863150 — intervention group
Group type: EXPERIMENTAL
Intervention: Children and patients with severe diseases
Number of subjects: 295
Study 8863150 — intervention group
Group type: EXPERIMENTAL
Intervention: Aged individuals, patients with mild diseases, and patients with self-acquired diseases
Number of subjects: 295
Study 8863150 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor or rich patients
Number of subjects: 295
Study 1353933 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ridazolol
Number of subjects: 15
Study 1353933 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg ridazolol
Number of subjects: 15
Study 1353933 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg ridazolol
Number of subjects: 15
Study 1353933 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg ridazolol
Number of subjects: 15
Study 6355394 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation therapy with spouse
Number of subjects: 31
Study 6355394 — intervention group
Group type: COMPARATOR
Intervention: Relaxation therapy alone
Number of subjects: 31
Study 6355394 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation therapy (both groups)
Number of subjects: 31